Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,501.65 0.00 0.00%
S&P 500 1,878.61 3.22 0.17%
NASDAQ 4,148.34 21.37 0.52%
Ticker Volume Price Price Delta
STOXX 50 3,168.64 -21.17 -0.66%
FTSE 100 6,688.34 -14.66 -0.22%
DAX 9,467.19 -81.49 -0.85%
Ticker Volume Price Price Delta
NIKKEI 14,429.26 24.27 0.17%
TOPIX 1,169.99 5.09 0.44%
HANG SENG 22,223.53 -339.27 -1.50%

Urologix Announces Important Milestone in Prostiva(R) RF Therapy Licensing Agreement



Urologix Announces Important Milestone in Prostiva(R) RF Therapy Licensing
Agreement

MINNEAPOLIS, April 8, 2013 (GLOBE NEWSWIRE) -- Urologix, Inc. (Nasdaq:ULGX),
the leading provider of in-office BPH therapy, today announced that it has
reached an important milestone in its licensing agreement with Medtronic for
the Prostiva RF Therapy System. In accordance with the terms of the agreement,
Urologix has become the licensed manufacturer for the Prostiva RF Therapy
System, taking manufacturing and regulatory responsibility for the product
line.

This milestone represents an important step in the integration of the Prostiva
product line into the broader Urologix organization and will allow the Company
to work directly with our manufacturing partners to ensure continued focus on
both quality and efficiency going forward. In addition, achieving this
milestone enables the Company to market and sell all Prostiva RF Therapy
products distributed throughout the United States under the Urologix brand
name.

"The Urologix team is well prepared and excited to take over the
responsibility for all aspects of the Prostiva system," said Greg Fluet, Chief
Executive Officer. "Our team can now present the two leading in-office BPH
technologies under one Urologix brand. These Urologix products enable our
urologist customers to optimize care for their patients who are frustrated
with the lack of value provided by drug therapies and are unwilling to undergo
more invasive surgical procedures."  

About Urologix

Urologix, Inc., based in Minneapolis, develops, manufactures, markets and
distributes minimally invasive medical products for the treatment of
obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). 
Urologix's Cooled ThermoTherapy™ produces targeted microwave energy combined
with a unique cooling mechanism to protect healthy tissue and enhance patient
comfort.  The Prostiva® RF Therapy System delivers radio frequency energy
directly into the prostate destroying prostate tissue, reducing constriction
of the urethra, and thereby relieving BPH symptoms. Both of these therapies
provide safe, effective and lasting relief of the symptoms and obstruction due
to BPH. Prostiva is a registered trademark of Medtronic, Inc., used under
license.  All other trademarks are the property of Urologix.

If you'd like more information on this topic, please contact Brian Smrdel at
(763) 475-7696 or bsmrdel@urologix.com or to learn more about Urologix and its
products and services, visit our website at www.urologix.com. 

The Urologix logo is available at
www.urologix.com/clinicians/resource-library.php.

Forward Looking Statements

This press release contains forward-looking statements that are made pursuant
to the safe harbor provisions of the Private Securities Litigation Reform Act
of 1995. Any statements contained in this press release that are not
statements of historical fact may be deemed to be forward-looking statements.
Without limiting the foregoing, words such as "may," "will," "expect,"
"believe," "anticipate," "estimate" or "continue" or comparable terminology
are intended to identify forward-looking statements. Such forward looking
statements include, for example, the Company's ability to successfully
manufacture the Prostiva RF Therapy System. The statements made by the Company
are based upon management's current expectations and are subject to certain
risks and uncertainties that could cause the actual results to differ
materially from those described in the forward-looking statements. These risks
and uncertainties include market conditions and other factors beyond the
Company's control and the risk factors and other cautionary statements
described in the Company's Annual Report on Form 10-K for the year ended June
30, 2012 and other documents filed with the Securities and Exchange
Commission.

Important Safety Information

The Targis System/Cooled ThermoTherapy is indicated to relieve symptoms and
obstruction associated with BPH in men with prostatic urethra lengths greater
than or equal to 2.5 cm. This treatment is contraindicated for patients with a
prostatic urethra <2.5 cm in length as measured from the bladder neck to the
verumontanum, with urethral stricture (unable to pass 22F urethroscope),
peripheral arterial disease with intermittent claudication or Leriches
Syndrome (i.e. claudication of the buttocks or perineum); patients who have
undergone pelvic radiation therapy or have implanted active devices, including
pacemakers or defibrillators within 2.6 inches (6.5 cm) of the prostatic
urethra.

For complete indications, contraindications, and precautions for Prostiva RF
Therapy, please refer to the Prostiva System Manual at www.urologix.com.

Caution: Federal USA law restricts these devices to sale by or on the order of
a physician. For more complete information about the benefits, risks and
contraindications associated with Cooled ThermoTherapy and Prostiva RF
Therapy, please refer to the product labeling packaged with the device or
refer to the System Manual/Instructions for Use found at www.urologix.com.

CONTACT: Urologix Investor Relations Contact
         Brian Smrdel
         (763) 475-7696
         Bsmrdel@urologix.com
        
         Urologix Media Contact
         Karen Jackson
         (513) 484-2987
         Kjackson@urologix.com

Urologix, Inc. Logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement